1. Lim S, Meigs JB. (2013). Ectopic fat and cardiometabolic and vascular risk. Int J Cardiol. 169: 166-176.

2. Deplanque D, Amarenco P Blood lipids and stroke: What more can we do besides reducing low-density lipoprotein cholesterol? Curr Atheroscler Rep. 2011; 13:306–313.

3. Holzer M, Trieb M, Konya V, i in. Aging affects high-density lipoprotein composition and function. Biochim Biophys Acta. 2013; 1831:1442-1448.

4. Besseling J, Kindt I, Hof M, i in. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. Atherosclerosis. 2014;233: 219-223.

5. Stock J. New EAS consensus statement on FH: Improving the care of FH. Atherosclerosis. 2013; 231: 69-71.

6. Casella-Filho A, Chagas AC, Maranhão RC, i in. Effect of exercise training on plasma levels and functional properties of high-density lipoprotein cholesterol in the metabolic syndrome. Am J Cardiol. 2011; 107: 1168-1172.

7. Bang CN, Gislason GH, Greve AM, Torp-Pedersen C, Køber L, Wachtell K. Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study. Eur J Prev Cardiol. 2014; 21: 330-338.

8. Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo- controlled trials to aid individual patient choice. Eur J Prev Cardiol. 2014; 21:464-474.

9. Takagi H, Umemoto T. A meta-analysis of randomized head-to-head trials of atorvastatin versus rosuvastatin for reductions in C-reactive proteins. Int J Cardiol. 2012; 154: 78-95.

10. Jiang Z, Gong RR, Qiu L, i in. Efficacy and safety of pitavastatin versus simvastatin: a meta-analysis of randomized controlled trials. Clin Drug Invest. 2014; 34: 599-608.

11. Virsanger M, Underberg JA. New treatment approaches for dyslipidemia and its management. Curr Cardiovasc Risk Rep. 2013; 7: 395-400.

12. Krzystyniak KL, Mucha D, Zięba H, Marszałek A. Wyzwania ekstremalne. Granice wytrzymałości człowieka. Warszawa: Wyd. Medyk; 2014.

13. Morrone D, Weintraub WS, Toth PP, i in. Lipid-altering ef cacy of ezetimibe plus statin and statin monotherapy and identi cation of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012; 223: 251-261. 

14. Bandeali SJ, Daye J, Virani SS. Novel therapies for treating familial hypercholesterolemia. Curr Atheroscler Rep. 2014; 16: 382-392.

15. Drakopoulu M, Toutouzas K, Stefanadis C. Novel pharmacotherapies of familial hyperlipidemia. Pharmacol Therapeut. 2013; 139: 301-312.

16. Wilkinson MJ, Davidson MHRecent developments in the treatment of familial hypercholesterolemia: A review of several new drug classes. Curr Treatm Opt Cardiovasc Med. 2013; 15: 696-705.

17. Thomas GS, Cromwell WC, Shariq Ali S. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013; 62: 2178-2184.

18. Stein EA, Gipe D, Bergeron J, i in. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012; 380:29-36.

19. Bays HE. Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus. Int J Gen Med. 2014; 7: 355-364.

20. Reiner Z. Resistance and intolerance to statins. Nutr Metabol Cardiovasc Dis. 2014; 24: 1057-1066.

21. Wilkinson MJ, Laffin LJ, Davidson MH. Overcoming toxicity and side- effects of lipid-lowering therapies. Best Practice Res Clin Endocrinol Metabol. 2014; 28: 439-452.

22. Cornier MA, Eckel RH. Non-traditional dosing of statins in statinintolerant patients – is it Worth a try? Curr Atheroscler Rep. 2015; 17: 475-482.

23. Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, i in. Analysis of vitamin D levels in patients with and without statin-associated malgia – A systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol. 2015; 178: 111-116.

24. Feingold KR Statin myopathy: A problem looking for solution. Atherosclerosis. 2015; 239: 85-86.

25. Norata GD, Tibolla G, Catapano AL Statins and skeletal muscle toxicity: From clinical trial to everyday practice. Pharmacol Res. 2014; 88: 107-113.